Avant Technologies' JV Partner, Ainnova, Begins Diabetic Retinopathy Screenings with Leading Pharmacies
LAS VEGAS, June 17, 2025 /CNW/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that screenings for diabetic retinopathy begin this week in collaboration with Grupo Dökka and its leading pharmacy subsidiaries, Fischel Pharmacies and La Bomba Pharmacies located in Central America.
Both Fischel and La Bomba Pharmacies have asked their diabetic customers to schedule a free screening as part of a collaborative program where Ainnova will use its cutting-edge AI platform, Vision AI, to help identify changes in the retina using a quick and non-invasive scan of the patient's retina.
Vinicio Vargas, Chief Executive Officer at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp., a joint venture company created by both Avant and Ainnova, said of the benefits for the collaboration, "As we begin similar initiatives in Mexico, our goal is to close the patient care loop with timely treatment—connecting every step of the journey. We are integrating pharma, retail, ophthalmologists, and our technology into a unified experience, all driven by one incentive: the well-being of the diabetic patient. Projects like this allow us to validate the model across diverse populations and sectors as part of our strategy to reach the market in a smarter, more efficient way—where the biggest winners are the patients."
Diabetic retinopathy is one of the main causes of vision loss in people with diabetes. Although, in its early stages, it may not present symptoms, it can be detected with a simple and quick screening. The screenings are important for:
Prevention: Screenings will detect changes in the retina before they affect vision.
Speed: Each screening takes only a few minutes.
Peace of Mind: Patients will receive the results of the screening in a secure and timely manner.
Grupo Dökka, which operates in Costa Rica, Nicaragua, and Panama with expansion expected into other Central American countries, has created numerous innovative platforms, including storage and distribution, pharmacies, and marketing and sales, that provide access to comprehensive health and well-being solutions for all people.
About Ainnova Tech, Inc.
Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.
About Avant Technologies, Inc.
Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.
More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:
https://twitter.com/AvantTechAI
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
3 hours ago
- Cision Canada
Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS
NEW YORK, /CNW/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) today announced that it is moving forward with manufacturing and process development work in preparation for clinical trials of KLTO-202, its investigational gene therapy for amyotrophic lateral sclerosis (ALS). A unique RNA splice variant of the human gene called alpha-Klotho has been licensed by the Company from the Autonomous University of Barcelona ("UAB") including patents, patent applications, research, knowhow and other intellectual properties for use in the development of advanced gene and gene-engineered cell therapies. The human alpha-Klotho gene is located in cells found throughout the human body. It is a five exon gene that produces two protein isoforms: a full-length protein found mainly in cells of the kidney called membrane-bound Klotho (or m-KL), which controls phosphate homeostasis, and a much smaller protein isoform called secreted alpha-Klotho (or s-KL). The s-KL RNA splice variant is found mainly in the brain and spinal cord neurons; the variant protein is neuroprotective by minimizing both oxidative stress and neuroinflammation. Animal studies supported by the Company over the past two years in mouse and non-human primate models of rapid aging, in models of human Alzheimer's disease, and in models of ALS have shown that over-expression and amplification of the tissue levels of s-KL using a gene therapy approach result in highly favorable therapeutic outcomes in every model tested. These results have been published in peer-reviewed scientific journals and now support the transition of KLTO-202 into the clinical development stage. The Company expects that it will take approximately eight months to complete process development and manufacturing of KLTO-202, and about four to six months to conduct meetings with FDA, complete all FDA-mandated animal safety studies, file an investigational new drug application (IND), train and prepare clinical sites where the Phase I/II studies can be conducted, and then begin the single-dose gene therapy studies in ALS patients by the third quarter of next year. The Company will work with contract research organizations (CROs) to facilitate all activities including manufacturing and clinical trials without the need to hire several dozen staff members, which would significantly increase our operating overhead. Dr. Joseph Sinkule, the Company's CEO and founder commented: "With our recent fundraising success, we're moving forward with manufacturing the s-KL transgene DNA for KLTO-202. We've identified a more efficient method of producing the AAV vector to deliver the s-KL gene directly to motor neurons—the cells most affected by ALS. Our goal is to increase local s-KL protein levels to protect these neurons from the damage that leads to voluntary and involuntary muscle paralysis and ultimately death." ALS typically progresses rapidly, with most patients losing mobility, respiratory function, and life within just 2–3 years of diagnosis. About Klotho Neurosciences, Inc. Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. The Company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. The Company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization. Investor Contact and Corporate Communications - Jeffrey LeBlanc, CFO [email protected] Forward-Looking Statements: This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company's future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company's inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
Edmonton Journal
2 days ago
- Edmonton Journal
Alberta judge grants temporary injunction blocking a transgender health-care bill
Article content 'This isn't just a win for trans youth, it is a win for Canada's health-care system,' Wells wrote on social media. 'No politician should be dictating or restricting your access to evidence-based medical care.' Egale and the Skipping Stone Foundation aren't the only groups challenging the bill. Last month, the Canadian Medical Association and three Alberta-based doctors launched a legal case challenging the constitutionality of the bill, arguing it violates their Charter right to freedom of conscience. Alberta's other two pieces of transgender legislation _ banning transgender women from competing in womens sports and preventing youth under 16 from changing their name or pronouns in the school system without parental consent — have yet to be challenged in court. The education bill also requires parents to opt in for their children to receive lessons in school on sexuality, sexual orientation and gender identity. — with files from Aaron Sousa
Canada News.Net
3 days ago
- Canada News.Net
Andhra Minister Nara Lokesh congratulates Jahnavi Dangeti over her selection in NASA's space mission
Amravati (Andhra Pradesh) [India], June 26 (ANI): Andhra Pradesh's Minister for Education, Nara Lokesh, met Astronaut candidate Jahnavi Dangeti, a native of Palakollu in West Godavari district, at her residence in Undavalli on Wednesday. Jahnavi has been selected as an astronaut candidate for the US-based private aerospace company Titans Space, earning the distinction of being the first Telugu woman from India to be chosen for a space mission, Nara Lokesh wrote on X. During the meeting, Lokesh congratulated Jahnavi on her remarkable achievement and praised her for bringing pride to Andhra Pradesh as a 'Telugu daughter.' He assured Jahnavi of the state government's full support and encouragement for her future endeavours. In the X post, Nara Lokesh wrote, 'I met Jahnavi Dangeti, a native of Palakollu in West Godavari district, who was selected as an astronaut candidate for the Titan Space Mission by the American private company, at her residence in Undavalli. Jahnavi has achieved the distinction of being the first Telugu woman from India to set foot in space. I congratulated Jahnavi on being selected as an astronaut candidate for the space mission. I praised her for standing as a source of pride for the state as a Telugu daughter. I assured her that the government would provide all kinds of encouragement in the future. I requested her to participate as a partner on behalf of the government in the STEM outreach activities undertaken by the Education Department.' Andhra Pradesh Governor S Abdul Nazeer also congratulated Dangeti Jahnavi for being chosen to complete NASA's prestigious International Air and Space Program. The social media platform X of the Andhra Governor said, 'Governor of Andhra Pradesh Sri S. Abdul Nazeer has congratulated India's Youngest Analog Astronaut, Ms. Dangeti Jahnavi hailing from Palakollu, West Godavari district of the State, for being the first Indian to complete the NASA's prestigious International Air and Space Program.' Jahnavi is set to travel to space as a part of the Astronaut Candidate (ASCAN) for US-based private aerospace company Titans Space for its EarthLoop Orbital Cruise mission in March 2029. (ANI)
